# Plain Language Summary: Tropical Disease Voucher Program for Coccidioidomycosis

This bill expands an existing government program designed to encourage pharmaceutical companies to develop treatments and prevention methods for rare tropical diseases. Specifically, it adds coccidioidomycosis—commonly called "Valley Fever"—to the list of diseases covered by this incentive program.

Here's how it works in practice: When a drug company successfully develops and gets FDA approval for a new medication to treat or prevent one of these designated tropical diseases, they receive a "priority review voucher." This voucher is essentially a valuable ticket that lets them fast-track the FDA approval process for a different drug they're developing, potentially saving them years of waiting time and millions of dollars. The company can even sell this voucher to another pharmaceutical company. The idea is that this financial incentive makes it worthwhile for companies to invest in treatments for diseases that don't affect huge populations in wealthy countries, since these diseases typically aren't as profitable as common conditions.

Valley Fever is a fungal infection that primarily affects people in the southwestern United States, particularly in Arizona and California, though it can also occur in parts of Mexico and Central America. The disease spreads through breathing in fungal spores from soil and can cause serious respiratory problems. By adding Valley Fever to this program, Congress is signaling that developing better treatments and prevention methods for this disease is a priority worth incentivizing. This could lead to more pharmaceutical research into Valley Fever medications and preventive measures, potentially giving patients better treatment options in the future.

A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

Kelly, Mark

  <p>This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.</p>